30 Stocks Moving In Monday’s Mid-Day Session
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
REGENXBIO Presents Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Suprachoroidal delivery of RGX-314 well tolerated in 50 patients in Cohorts 1-3 with no drug-related serious adverse events
Positive initial data from Cohort 1 at six months after one-time treatment of
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
RBC Capital Maintains Sector Perform on Regenxbio, Raises Price Target to $55
RBC Capital analyst Luca Issi maintains Regenxbio (NASDAQ:RGNX) with a Sector Perform and raises the price target from $50 to $55.
Barclays Maintains Overweight on Regenxbio, Raises Price Target to $82
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $79 to $82.
45 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets.
Why Regenxbio Shares Are Trading Higher Today
Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration.